Ancillary Care Management (ACM) says the program will support coverage of injectable and infusion therapy services under the Medicare Part D program, a prescription drug plan designed to help improve quality of care and increase access to affordable drug coverage for Medicare beneficiaries nationwide.
Over the past year, ACM has conducted extensive research and invested significant resources to develop a solution that addresses the gaps in Medicare Part D coverage related to the services and equipment needed to administer the drugs for injectable and infusion therapies. The InfuseD program is designed to address these gaps in coverage and provide payers and providers with an effective tool for the management of drugs, services, and equipment for injectable and infusion therapy.
ACM also claims its clients will receive sophisticated claims administration technology and clinical expertise from ACM for managing the network and program.
David Willcutts, ACM’s CEO said, While offering exciting new coverage, Medicare Part D creates challenges for seniors in understanding how to utilize this benefit for complex injectable and infusion drug therapies. ACM is pleased to assist its clients in offering choice and convenience to seniors who enroll in their Medicare plans and programs.
